Trevi Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Updates
Trevi Therapeutics (TRVI) reported third-quarter 2026 financial results characterized by increased research and development spending driven by its OCEAN and LAKE clinical trials. The company recorded a net loss of $21.5 million for the quarter, compared to $11.8 million in the prior year period, resulting in a net loss per share of $0.13. Despite higher operating costs, Trevi significantly strengthened its liquidity position, reporting cash and marketable securities of $299.4 million as of September 30, 2026. Management highlighted an extended cash runway reaching into 2030, which they believe is sufficient to fund lead clinical programs through potential FDA approval. Key upcoming milestones include top-line results from the OCEAN-2 Phase III trial in the second half of 2027 and the LAKE Phase IIb trial statistical analysis in early Q1 2027. The company also secured a new patent allowance for nalbuphine ER dosing, extending intellectual property protection for certain indications until 2041.
Tickers: $TRVI
Topics: cash runway clinical trials earnings report net loss